

A Control Approach for ODE Cancer Models

Khalid Kassara

MACS://Systems & Control Group
University Hassan II, Casablanca

8th ECMTB, **Krakow** (PL)

Outline

1 Motivations of the work

2 A control approach

- Statement of the problem
- The set-valued framework
- Cancer control

3 Simulation results

- Anti-angiogenic therapy
- Tumor-immune interactions with chemotherapy
- Immunotherapy

Outline

1 Motivations of the work

2 A control approach

- Statement of the problem
- The set-valued framework
- Cancer control


3 Simulation results

- Anti-angiogenic therapy
- Tumor-immune interactions with chemotherapy
- Immunotherapy

Mathematical modeling and cancer

- ▶ central role in cancer research, to understand how tumors develop
- ▶ control theory : for fighting cancer through mathematical models
 - **optimal control** : criterion minimized \implies cancer cells reduced
Bellomo, de Pillis, D'Onofrio, Fister, Ledzewicz, Lenhart, Piccoli etc
 - **direct approach**
 - for PDEs,

by using spreading control
El Jai , Kassara, IJC (2006)




- for ODEs,
Kassara, Moustafid, in MCM, PAMM, SIAM J. Cont., MB (2006-2011)
- other approaches : agent-based modeling, cellular automata, stochastic, etc

Mathematical modeling and cancer

- ▶ central role in cancer research, to understand how tumors develop
- ▶ control theory : for fighting cancer through mathematical models
 - **optimal control** : criterion minimized \implies cancer cells reduced
Bellomo, de Pillis, D'Onofrio, Fister, Ledzewicz, Lenhart, Piccoli etc
 - direct approach
 - for PDEs,

by using spreading control
El Jai , Kassara, IJC (2006)




- for ODEs,
Kassara, Moustafid, in MCM, PAMM, SIAM J. Cont., MB (2006-2011)
- other approaches : agent-based modeling, cellular automata, stochastic, etc

Mathematical modeling and cancer

- ▶ central role in cancer research, to understand how tumors develop
- ▶ control theory : for fighting cancer through mathematical models
 - **optimal control** : criterion minimized \implies cancer cells reduced
Bellomo, de Pillis, D'Onofrio, Fister, Ledzewicz, Lenhart, Piccoli etc
 - **direct approach**
 - for PDEs,

by using spreading control
El Jai , Kassara, IJC (2006)




- for ODEs,
Kassara, Moustafid, in MCM, PAMM, SIAM J. Cont., MB (2006-2011)
- other approaches : agent-based modeling, cellular automata, stochastic, etc

Mathematical modeling and cancer

- ▶ central role in cancer research, to understand how tumors develop
- ▶ control theory : for fighting cancer through mathematical models
 - **optimal control** : criterion minimized \implies cancer cells reduced
Bellomo, de Pillis, D'Onofrio, Fister, Ledzewicz, Lenhart, Piccoli etc
 - **direct approach**
 - for **PDEs**,

by using **spreading control**
El Jai , Kassara, IJC (2006)




- for **ODEs**,
Kassara, Moustafid, in MCM, PAMM, SIAM J. Cont., MB (2006-2011)
- other approaches : agent-based modeling, cellular automata, stochastic, etc

Mathematical modeling and cancer

- ▶ central role in cancer research, to understand how tumors develop
- ▶ control theory : for fighting cancer through mathematical models
 - **optimal control** : criterion minimized \implies cancer cells reduced
Bellomo, de Pillis, D'Onofrio, Fister, Ledzewicz, Lenhart, Piccoli etc
 - **direct approach**
 - for **PDEs**,

by using **spreading control**
El Jai , Kassara, IJC (2006)



- for **ODEs**,
Kassara, Moustafid, in MCM, PAMM, SIAM J. Cont., MB (2006-2011)
- other approaches : agent-based modeling, cellular automata, stochastic, etc

Outline

1 Motivations of the work

2 **A control approach**

- Statement of the problem
- The set-valued framework
- Cancer control

3 Simulation results

- Anti-angiogenic therapy
- Tumor-immune interactions with chemotherapy
- Immunotherapy

Cancer as a control problem

$$\begin{aligned}\dot{x} &= f(x, \tau) + G(x, \tau)u \\ \dot{\tau} &= \tau\psi(x, \tau)\end{aligned}$$

- ▶ $u \rightarrow K$
administered cells
- ▶ $K \doteq [0, u_1^{\max}] \times \cdots \times [0, u_p^{\max}]$
- ▶ τ tumor cells
- ▶ $x \rightarrow \mathbb{R}_+^n$ cells in competition
with tumor cells
- ▶ f, G, ψ smooth functions

Definition

A **protocol** is a control \bar{u} :

- 1 $\bar{u} : [0, \infty) \rightarrow K$
- 2 the system has a
global solution $(\bar{x}, \bar{\tau})$
- 3 $\lim_{t \rightarrow \infty} \bar{\tau}(t) = 0$

The feedback map

For $\beta > 0$ let $D_\beta \doteq \{(x, \tau) \in \mathbb{R}_+^n \times \mathbb{R}_+ \mid \psi(x, \tau) \leq -\beta\}$, and

$$\mathcal{F}_\beta(x, \tau) \doteq \left\{ u \in K \mid (f(x, \tau) + G(x, \tau)u, \tau\psi(x, \tau)) \in T_{D_\beta}(x, \tau) \right\}$$

for each $(x, \tau) \in D_\beta$, where $T_D(\cdot)$ is the contingent cone. Assume the linear growth condition : there are $m_1(\cdot)$, $m_2(\cdot)$, continuous such that :

$$|f(x, \tau)| \leq m_1(\tau)|x| \text{ and } |G(x, \tau)| \leq m_2(\tau)|x| \text{ on } D_\beta$$

Then Aubin viability theory leads to

Theorem :

- If σ is a selection of \mathcal{F}_β and $(x_0, \tau_0) \in D_\beta$, then
 - feedback $u = \sigma(x, \tau)$ produces a solution $(\bar{x}, \bar{\tau})$ on $[0, \infty)$
 - $\bar{u} = \sigma(\bar{x}, \bar{\tau})$ is a protocol and $\bar{x}(\cdot) \searrow 0$, exponentially (such σ is called a feedback law)

The feedback map

For $\beta > 0$ let $D_\beta \doteq \{(x, \tau) \in \mathbb{R}_+^n \times \mathbb{R}_+ \mid \psi(x, \tau) \leq -\beta\}$, and

$$\mathcal{F}_\beta(x, \tau) \doteq \left\{ u \in K \mid (f(x, \tau) + G(x, \tau)u, \tau\psi(x, \tau)) \in T_{D_\beta}(x, \tau) \right\}$$

for each $(x, \tau) \in D_\beta$, where $T_D(\cdot)$ is the contingent cone. Assume **the linear growth condition** : there are $m_1(\cdot)$, $m_2(\cdot)$, continuous such that :

$$|f(x, \tau)| \leq m_1(\tau)|x| \text{ and } |G(x, \tau)| \leq m_2(\tau)|x| \text{ on } D_\beta$$

Then **Aubin viability** theory leads to

Theorem :

If σ is a selection of \mathcal{F}_β and $(x_0, \tau_0) \in D_\beta$, then

- feedback $u \doteq \sigma(x, \tau)$ produces a solution $(\bar{x}, \bar{\tau})$ on $[0, \infty)$
- $\bar{u} \doteq \sigma(\bar{x}, \bar{\tau})$ is a protocol and $\bar{\tau}(\cdot) \searrow 0$, exponentially (such σ is called a **protocol law**)

The feedback map

For $\beta > 0$ let $D_\beta \doteq \{(x, \tau) \in \mathbb{R}_+^n \times \mathbb{R}_+ \mid \psi(x, \tau) \leq -\beta\}$, and

$$\mathcal{F}_\beta(x, \tau) \doteq \left\{ u \in K \mid (f(x, \tau) + G(x, \tau)u, \tau\psi(x, \tau)) \in T_{D_\beta}(x, \tau) \right\}$$

for each $(x, \tau) \in D_\beta$, where $T_D(\cdot)$ is the contingent cone. Assume **the linear growth condition** : there are $m_1(\cdot)$, $m_2(\cdot)$, continuous such that :

$$|f(x, \tau)| \leq m_1(\tau)|x| \text{ and } |G(x, \tau)| \leq m_2(\tau)|x| \text{ on } D_\beta$$

Then **Aubin viability** theory leads to

Theorem :

If σ is a selection of \mathcal{F}_β and $(x_0, \tau_0) \in D_\beta$, then

- feedback $u \doteq \sigma(x, \tau)$ produces a solution $(\bar{x}, \bar{\tau})$ on $[0, \infty)$
- $\bar{u} \doteq \sigma(\bar{x}, \bar{\tau})$ is a protocol and $\bar{\tau}(\cdot) \searrow 0$, exponentially (such σ is called a **protocol law**)

Expression of the feedback map

For each $(x, \tau) \in D_\beta$ we have,

$$\mathcal{F}_\beta(x, \tau) = \begin{cases} K & \text{if } \psi(x, \tau) < -\beta, \\ C(x, \tau) & \text{if } \psi(x, \tau) = -\beta, \end{cases}$$

where,

$$C(x, \tau) \doteq \{u \in K \mid \langle h(x, \tau), u \rangle \geq \ell(x, \tau)\},$$

and h, ℓ are given by,

$$h \doteq -G' \nabla_x \psi,$$

$$\ell \doteq \langle \nabla_x \psi, f \rangle + \tau \psi \frac{\partial \psi}{\partial \tau}$$

Two sets of protocol laws

Further the linear growth condition, assume **the qualification condition**

for all $(x, \tau) \in D_\beta$, there is $u \in K : \langle h(x, \tau), u \rangle > \ell(x, \tau)$

then :

- minimal protocol law

$$\zeta_{\min}(x, \tau) \doteq \begin{cases} 0 & \text{if } \psi(x, \tau) < -\beta \\ \pi_{C(x, \tau)}(0) & \text{if } \psi(x, \tau) = -\beta \end{cases}$$

π : the projector

- continuous protocol law

$$\zeta_\lambda(x, \tau) \doteq e^{\lambda(\psi(x, \tau) + \beta)} \pi_{C(x, \tau)}(0) \quad (\lambda > 0)$$

for each $(x, \tau) \in D_\beta$

Two sets of protocol laws

Further the linear growth condition, assume **the qualification condition**

for all $(x, \tau) \in D_\beta$, there is $u \in K : \langle h(x, \tau), u \rangle > \ell(x, \tau)$

then :

- minimal protocol law

$$\zeta_{\min}(x, \tau) \doteq \begin{cases} 0 & \text{if } \psi(x, \tau) < -\beta \\ \pi_{C(x, \tau)}(0) & \text{if } \psi(x, \tau) = -\beta \end{cases}$$

π : the projector

- continuous protocol law

$$\zeta_\lambda(x, \tau) \doteq e^{\lambda(\psi(x, \tau) + \beta)} \pi_{C(x, \tau)}(0) \quad (\lambda > 0)$$

for each $(x, \tau) \in D_\beta$

Two sets of protocol laws

Further the linear growth condition, assume the qualification condition

for all $(x, \tau) \in D_\beta$, there is $u \in K : \langle h(x, \tau), u \rangle > \ell(x, \tau)$

then :

- minimal protocol law

$$\zeta_{\min}(x, \tau) \doteq \begin{cases} 0 & \text{if } \psi(x, \tau) < -\beta \\ \pi_{C(x, \tau)}(0) & \text{if } \psi(x, \tau) = -\beta \end{cases}$$

π : the projector

- continuous protocol law

$$\zeta_\lambda(x, \tau) \doteq e^{\lambda(\psi(x, \tau) + \beta)} \pi_{C(x, \tau)}(0) \quad (\lambda > 0)$$

for each $(x, \tau) \in D_\beta$

Two sets of protocol laws

Further the linear growth condition, assume the qualification condition

for all $(x, \tau) \in D_\beta$, there is $u \in K : \langle h(x, \tau), u \rangle > \ell(x, \tau)$

then :

- minimal protocol law

$$\zeta_{\min}(x, \tau) \doteq \begin{cases} 0 & \text{if } \psi(x, \tau) < -\beta \\ \pi_{C(x, \tau)}(0) & \text{if } \psi(x, \tau) = -\beta \end{cases}$$

π : the projector

- continuous protocol law

$$\zeta_\lambda(x, \tau) \doteq e^{\lambda(\psi(x, \tau) + \beta)} \pi_{C(x, \tau)}(0) \quad (\lambda > 0)$$

for each $(x, \tau) \in D_\beta$

A strategy to eliminate cancer cells

(x, τ) is said to be at **stage I** if $\psi(x, \tau) < 0$, at **stage II** if $\psi(x, \tau) \geq 0$ and it is *amenable* to stage I. Otherwise it is said to be at **stage III**

(i) For (x_0, τ_0) at **stage I**, let $\beta = -\psi(x_0, \tau_0)$

▶ apply a protocol law on D_β

- **minimal** if preference is to reduce amount of doses
- **continuous** if smoothness is rather required

▶ $\bar{\tau}(\cdot)$ will **decrease** and $\bar{\tau}(t) \leq e^{-\beta t} \tau_0$ for all t

(ii) For (x_0, τ_0) at **stage II**, bring it to stage I and apply (i)

A method :

▶ let ξ be a continuous selection of the map

$$C_\lambda(x, \tau) \doteq \{u \in K \mid \langle h(x, \tau), u \rangle - l(x, \tau) \geq \lambda\} \quad (\lambda > 0)$$

▶ apply feedback control $u = \xi(x, \tau)$, and assume that the system has a solution $(\bar{x}, \bar{\tau})$ on horizon $[0, t_{im}]$, where $t_{im} > \psi(x_0, \tau_0)/\lambda$

▶ set $(x_1, \tau_1) \doteq (\bar{x}(t_{im}), \bar{\tau}(t_{im}))$, then (x_1, τ_1) is at **stage I**

(iii) For (x_0, τ_0) at **stage III** : not curable

A strategy to eliminate cancer cells

(x, τ) is said to be at **stage I** if $\psi(x, \tau) < 0$, at **stage II** if $\psi(x, \tau) \geq 0$ and it is *amenable* to stage I. Otherwise it is said to be at **stage III**

(i) For (x_0, τ_0) at **stage I**, let $\beta = -\psi(x_0, \tau_0)$

- ▶ apply a protocol law on D_β
 - **minimal** if preference is to reduce amount of doses
 - **continuous** if smoothness is rather required
- ▶ $\bar{\tau}(\cdot)$ will **decrease** and $\bar{\tau}(t) \leq e^{-\beta t} \tau_0$ for all t

(ii) For (x_0, τ_0) at **stage II**, bring it to stage I and apply (i)

A method :

- ▶ let ξ be a continuous selection of the map

$$C_\lambda(x, \tau) \doteq \{u \in K \mid \langle h(x, \tau), u \rangle - \ell(x, \tau) \geq \lambda\} \quad (\lambda > 0)$$

- ▶ apply feedback control $u = \xi(x, \tau)$, and assume that the system has a solution $(\bar{x}, \bar{\tau})$ on horizon $[0, t_{im}]$, where $t_{im} > \psi(x_0, \tau_0)/\lambda$
- ▶ set $(x_1, \tau_1) \doteq (\bar{x}(t_{im}), \bar{\tau}(t_{im}))$, then (x_1, τ_1) is at **stage I**

(iii) For (x_0, τ_0) at **stage III** : not curable

A strategy to eliminate cancer cells

(x, τ) is said to be at **stage I** if $\psi(x, \tau) < 0$, at **stage II** if $\psi(x, \tau) \geq 0$ and it is *amenable* to stage I. Otherwise it is said to be at **stage III**

(i) For (x_0, τ_0) at **stage I**, let $\beta = -\psi(x_0, \tau_0)$

- ▶ apply a protocol law on D_β
 - **minimal** if preference is to reduce amount of doses
 - **continuous** if smoothness is rather required
- ▶ $\bar{\tau}(\cdot)$ will **decrease** and $\bar{\tau}(t) \leq e^{-\beta t} \tau_0$ for all t

(ii) For (x_0, τ_0) at **stage II**, bring it to stage I and apply (i)

A method :

- ▶ let ξ be a continuous selection of the map

$$C_\lambda(x, \tau) \doteq \{u \in K \mid \langle h(x, \tau), u \rangle - \ell(x, \tau) \geq \lambda\} \quad (\lambda > 0)$$

- ▶ apply feedback control $u = \xi(x, \tau)$, and assume that the system has a solution $(\bar{x}, \bar{\tau})$ on horizon $[0, t_{im}]$, where $t_{im} > \psi(x_0, \tau_0)/\lambda$
- ▶ set $(x_1, \tau_1) \doteq (\bar{x}(t_{im}), \bar{\tau}(t_{im}))$, then (x_1, τ_1) is at **stage I**

(iii) For (x_0, τ_0) at **stage III** : not curable

A strategy to eliminate cancer cells

(x, τ) is said to be at **stage I** if $\psi(x, \tau) < 0$, at **stage II** if $\psi(x, \tau) \geq 0$ and it is *amenable* to stage I. Otherwise it is said to be at **stage III**

(i) For (x_0, τ_0) at **stage I**, let $\beta = -\psi(x_0, \tau_0)$

- ▶ apply a protocol law on D_β
 - **minimal** if preference is to reduce amount of doses
 - **continuous** if smoothness is rather required
- ▶ $\bar{\tau}(\cdot)$ will **decrease** and $\bar{\tau}(t) \leq e^{-\beta t} \tau_0$ for all t

(ii) For (x_0, τ_0) at **stage II**, bring it to stage I and apply (i)

A method :

- ▶ let ξ be a continuous selection of the map

$$C_\lambda(x, \tau) \doteq \{u \in K \mid \langle h(x, \tau), u \rangle - \ell(x, \tau) \geq \lambda\} \quad (\lambda > 0)$$

- ▶ apply feedback control $u = \xi(x, \tau)$, and assume that the system has a solution $(\bar{x}, \bar{\tau})$ on horizon $[0, t_{im}]$, where $t_{im} > \psi(x_0, \tau_0)/\lambda$
- ▶ set $(x_1, \tau_1) \doteq (\bar{x}(t_{im}), \bar{\tau}(t_{im}))$, then (x_1, τ_1) is at **stage I**

(iii) For (x_0, τ_0) at **stage III** : not curable

A strategy to eliminate cancer cells

(x, τ) is said to be at **stage I** if $\psi(x, \tau) < 0$, at **stage II** if $\psi(x, \tau) \geq 0$ and it is *amenable* to stage I. Otherwise it is said to be at **stage III**

(i) For (x_0, τ_0) at **stage I**, let $\beta = -\psi(x_0, \tau_0)$

- ▶ apply a protocol law on D_β
 - **minimal** if preference is to reduce amount of doses
 - **continuous** if smoothness is rather required
- ▶ $\bar{\tau}(\cdot)$ will **decrease** and $\bar{\tau}(t) \leq e^{-\beta t} \tau_0$ for all t

(ii) For (x_0, τ_0) at **stage II**, bring it to stage I and apply (i)

A method :

- ▶ let ξ be a continuous selection of the map

$$C_\lambda(x, \tau) \doteq \{u \in K \mid \langle h(x, \tau), u \rangle - \ell(x, \tau) \geq \lambda\} \quad (\lambda > 0)$$

- ▶ apply feedback control $u = \xi(x, \tau)$, and assume that the system has a solution $(\bar{x}, \bar{\tau})$ on horizon $[0, t_{im}]$, where $t_{im} > \psi(x_0, \tau_0)/\lambda$
- ▶ set $(x_1, \tau_1) \doteq (\bar{x}(t_{im}), \bar{\tau}(t_{im}))$, then (x_1, τ_1) is at **stage I**

(iii) For (x_0, τ_0) at **stage III** : not curable

A strategy to eliminate cancer cells

(x, τ) is said to be at **stage I** if $\psi(x, \tau) < 0$, at **stage II** if $\psi(x, \tau) \geq 0$ and it is *amenable* to stage I. Otherwise it is said to be at **stage III**

- (i) For (x_0, τ_0) at **stage I**, let $\beta = -\psi(x_0, \tau_0)$
- ▶ apply a protocol law on D_β
 - **minimal** if preference is to reduce amount of doses
 - **continuous** if smoothness is rather required
 - ▶ $\bar{\tau}(\cdot)$ will **decrease** and $\bar{\tau}(t) \leq e^{-\beta t} \tau_0$ for all t
- (ii) For (x_0, τ_0) at **stage II**, bring it to stage I and apply (i)

A method :

- ▶ let ξ be a continuous selection of the map

$$C_\lambda(x, \tau) \doteq \{u \in K \mid \langle h(x, \tau), u \rangle - \ell(x, \tau) \geq \lambda\} \quad (\lambda > 0)$$

- ▶ apply feedback control $u = \xi(x, \tau)$, and assume that the system has a solution $(\bar{x}, \bar{\tau})$ on horizon $[0, t_{\text{im}}]$, where $t_{\text{im}} > \psi(x_0, \tau_0)/\lambda$
- ▶ set $(x_1, \tau_1) \doteq (\bar{x}(t_{\text{im}}), \bar{\tau}(t_{\text{im}}))$, then (x_1, τ_1) is at **stage I**

- (iii) For (x_0, τ_0) at **stage III** : not curable

A more general class of models

$$\begin{aligned}\dot{x} &= f(x, \tau) + G(x, \tau)u \\ \dot{\tau} &= \tau(\psi(x, \tau) + H(x, \tau)v)\end{aligned}$$

- ▶ $(u, v) \rightarrow K \subset \mathbb{R}^p \times \mathbb{R}^q$ administered cells
- ▶ τ tumor cells
- ▶ x cells in competition with tumor cells

Method : recover the previous setting as follows :

- ▶ let $z \doteq (x, v)'$
- ▶ define $\varphi(z, \tau) \doteq \psi(x, \tau) + H(x, \tau)v$
- ▶ consider the augmented system, controlled by (u, w) ,

$$\begin{aligned}\dot{z} &= (f(x, \tau) + G(x, \tau)u, w)' \\ \dot{\tau} &= \tau\varphi(z, \tau)\end{aligned}$$

Outline

1 Motivations of the work

2 A control approach

- Statement of the problem
- The set-valued framework
- Cancer control

3 **Simulation results**

- Anti-angiogenic therapy
- Tumor-immune interactions with chemotherapy
- Immunotherapy

Hahnfeldt et al. model

Cancer Res. 59 (1999)

- x endothelial cells,
- u inhibitors dose



$$\dot{x} = -\mu x + S(x, \tau) - I(x, \tau) - Gxu$$

$$\dot{\tau} = \tau \psi_{\alpha}(x, \tau)$$

with

$$S(x, \tau) \doteq b\tau^{\gamma} x^{1-\gamma},$$

$$I(x, \tau) \doteq d\tau^{\frac{2}{3}} x$$





de Pillis et al. model

Math. Biosc. 209 (2007)

- x_1 effector-immune cells,
- x_2 lymphocytes,
- x_3 chemotherapy
- u_1 chemotherapy drugs,
- u_2 external effector-immune cells

$$\begin{aligned}\dot{x}_1 &= g \frac{\tau}{h + \tau} x_1 - r x_1 - p x_1 \tau \\ &\quad - k_1 x_1 x_3 + s_1 u_1, \\ \dot{x}_2 &= -\delta x_2 - k_2 x_3 x_2 + s_2, \\ \dot{x}_3 &= -\gamma x_3 + u_2, \\ \dot{\tau} &= a\tau(1 - b\tau) - c_1 x_1 \tau - k_3 x_3 \tau\end{aligned}$$




Panetta-Kirschner model

J. Math. Biol. 37(1998)



$$\begin{aligned}\dot{x}_1 &= c_T - \mu_2 x_1 + \frac{p_1 x_1 x_2}{g_1 + x_2} + s_1 u_1 \\ \dot{x}_2 &= \frac{p_2 x_1 \tau}{g_3 + \tau} - \mu_3 x_2 + s_2 u_2 \\ \dot{\tau} &= \tau(r_2(1 - b_T) - \frac{ax_1}{g_2 + \tau})\end{aligned}$$

- ▶ x_1 effector cells
- ▶ x_2 interleukin
- ▶ u_1 source of effector cells
- ▶ u_2 source of interleukin



Results

- $\mu_2 = 0.1667, p_1 = 0.6917$
- $g_1 = 0.02, g_2 = 10^{-4}, r_2 = 1$
- $a = 5.5556, b = 1$
- $\mu_3 = 55.5556, p_2 = 27.778, g_3 = 10^{-6}$
- $s_1 = 600$ and $c = 0.1388$
- initial data :
 $x_0^1 = 1, x_0^2 = 1.2, \tau_0 = 10$



Summary

Conclusion

- universal formulas for the protocols
- curability of a cancer depends on its initial stage
- minimality and smoothness of a protocol highlighted
- exponential estimates to control the session duration
- can be applied to other diseases

Open problems

- study more general classes of ODE models
- extend to PDE cancer models : similar results may hold for semilinear parabolic models

Summary

Conclusion

- universal formulas for the protocols
- curability of a cancer depends on its initial stage
- minimality and smoothness of a protocol highlighted
- exponential estimates to control the session duration
- can be applied to other diseases

Open problems

- study more general classes of ODE models
- extend to PDE cancer models : similar results may hold for semilinear parabolic models